Modulation of the AGAT/homoarginine pathway in cardio - vascular diseases


Förderkennzeichen

81Z1710102

Projektnummer

447

Institution
Universitätsklinikum Hamburg-Eppendorf
Projektleiter
Edzard Schwedhelm
Standort
Hamburg/Kiel/Lübeck
Kurzbeschreibung

L-arginine:glycine amidinotransferase (AGAT) is involved in creatine as well as homoarginine (hArg) synthesis. hArg is an amino acid identified as risk marker in cardiovascular (CV) and … 

L-arginine:glycine amidinotransferase (AGAT) is involved in creatine as well as homoarginine (hArg) synthesis. hArg is an amino acid identified as risk marker in cardiovascular (CV) and cerebrovascular diseases. Cardiac phenotyping of AGAT deficient, Mybpc3-targeted knock-in, and CREB-regulated transcription coactivator 1 deficient mice is part of the project for a better understanding of processes in CV diseases. The aim of the project is to investigate the potential relevance of the AGAT/hArg pathway as a new therapeutic approach in CV diseases, e.g. atrial fibrillation, stroke/transient ischemic attack, heart failure, and hypertrophic cardiomyopathy with AGAT modulators, identified by high throughput screening, and homoarginine supplementation in healthy and diseased patients.

Projektart
Standortprojekt
Stichwörter
AGAT, CRTC1, homoarginine
Fördersumme
€ 368.000,00
Beginn
29.10.2014
Ende
31.12.2018